Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion type Assertion NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_head.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion description "[We have developed a cancer-specific immunotherapy called modified CTL therapy, which involves adoptive immunotherapy of autologous cancer-specific bulk CTLs after active immunization of autologous or allogeneic cancer cells screened as in vitro stimulators according to their ability to induce autologous cancer-specific CTLs (ACS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion evidence source_evidence_literature NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion SIO_000772 11078795 NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion wasDerivedFrom befree-20150227 NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.
- NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_assertion wasGeneratedBy ECO_0000203 NP957770.RAphb8fOrjyYCU33gTLXaA30OwRFaLnXq1hPj5NT6tm8k130_provenance.